| Carli, Francesco |
| Recruiting | N/A | 54 | Canada | Prehabilitation | McGill University Health Centre/Research Institute of the McGill University Health Centre | Esophageal Cancer | 06/22 | 11/22 | | |
NCT04799561: Teleprehabilitation for Surgical Cancer Patients |
|
|
| Recruiting | N/A | 100 | Canada | Multimodal Teleprehabilitation, Virtual Prehabilitation | McGill University Health Centre/Research Institute of the McGill University Health Centre, Montreal General Hospital, Peri Operative Program, Montreal | Abdominal Cancer, Thoracic Cancer | 09/22 | 12/22 | | |
| Patel, Hema |
| Recruiting | 3 | 3286 | Europe | Norepinephrine, Balanced Crystalloid | NHS Greater Glasgow and Clyde, University of Edinburgh, Northern Care Alliance NHS Foundation Trust, University of Manchester, University of Glasgow, NHS Lothian, Chelsea and Westminster NHS Foundation Trust | Sepsis | 07/25 | 09/25 | | |
| magder, sheldon |
| Recruiting | 3 | 900 | Canada | acetaminophen, placebo | McGill University Health Centre/Research Institute of the McGill University Health Centre, Montreal Heart Institute, University of Manitoba, Canadian Institutes of Health Research (CIHR) | Delirium | 09/24 | 12/24 | | |
| Kimoff, John R |
HO2F, NCT03254212: Nocturnal Oxygen Needs and Central Sleep Apnea in Patients With Chronic Heart Failure. |
|
|
| Recruiting | 4 | 14 | Canada | Titration of nocturnal oxygen needs to prevent desaturations | Laval University, Oxynov, Philips Respironics | Chronic Heart Failure, Central Sleep Apnea | 10/22 | 12/22 | | |
NCT03309826: Positive Airway Pressure Treatment of Obstructive Sleep-disordered Breathing in Hypertensive Disorders of Pregnancy |
|
|
| Completed | N/A | 48 | Canada | Positive Airway Pressure, PAP, Nasal Dilator Strip | Dr John Kimoff, Canadian Institutes of Health Research (CIHR), ResMed Canada Inc. | Hypertensive Disorder of Pregnancy, Sleep Apnea, Obstructive | 07/21 | 12/21 | | |
| Solymoss, Susan |
COBRRA, NCT03266783: Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism |
|
|
| Recruiting | 4 | 2760 | Europe, Canada, RoW | Apixaban, Eliquis, Rivaroxaban, Xarelto | Ottawa Hospital Research Institute, Canadian Institutes of Health Research (CIHR), Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network | Venous Thromboembolism | 08/24 | 12/24 | | |
| Recruiting | N/A | 1276 | Europe, Canada | Limited cancer screening, Limited cancer screening + FDG PET/CT | University Hospital, Brest, Ministry of Health, France, Canadian Institutes of Health Research (CIHR), Ottawa Hospital Research Institute | Embolism and Thrombosis | 09/26 | 09/30 | | |
| Genest, Jacques |
NCT02009345: Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale Canada |
|
|
| Recruiting | N/A | 6000 | Canada | | McGill University Health Centre/Research Institute of the McGill University Health Centre, Amgen, Sanofi, Pfizer, Merck Sharp & Dohme LLC, Valeant Canada Limited, Aegerion Pharmaceuticals, Inc. | Familial Hypercholesterolemia, Lipid Disorder | 11/25 | 11/28 | | |
| Active, not recruiting | N/A | 65 | Canada | | McGill University Health Centre/Research Institute of the McGill University Health Centre, McGill University | Acute Coronary Syndrome | 12/25 | 12/25 | | |
NCT02135705: LOWER: Lomitapide Observational Worldwide Evaluation Registry |
|
|
| Recruiting | N/A | 300 | Europe, Canada, US, RoW | Lomitapide, Juxtapid, Lojuxta | Amryt Pharma | Homozygous Familial Hypercholesterolemia | 03/28 | 09/28 | | |
|
| Legault, Laurent |
| Not yet recruiting | 3 | 300 | Europe, Canada, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Weight Gain | 05/27 | 06/27 | | |
FCL, NCT06046417: A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 Diabetes |
|
|
| Recruiting | 2/3 | 30 | Canada | Pramlintide, Lyumjev, Automated Insulin Delivery (AID) system | McGill University Health Centre/Research Institute of the McGill University Health Centre, Juvenile Diabetes Research Foundation | type1diabetes, Diabetes Mellitus, Type 1 | 04/25 | 06/25 | | |
Lilly-MEALS, NCT06021158: A Trial to Compare Automated Lyumjev Delivery With Carbohydrate Counting, Qualitative Meal-size Estimation, and Meal Detection in Type 1 Diabetes |
|
|
| Recruiting | 2 | 12 | Canada | Hybrid automated Lyumjev delivery system with carbohydrate counting, Hybrid automated Lyumjev delivery system with meal size estimation, Fully automated Lyumjev delivery system with meal detection | McGill University Health Centre/Research Institute of the McGill University Health Centre | Diabetes Mellitus, Type 1, Type 1 Diabetes | 12/24 | 12/24 | | |
NCT04612257: Assessing Closed-loop Insulin Delivery in Children With Type 1 Diabetes. |
|
|
| Terminated | N/A | 10 | Canada | Insulin-alone closed-loop | McGill University, Eli Lilly and Company | Diabetes Mellitus, Type 1 | 06/22 | 06/22 | | |
NCT05041621: A Learning Algorithm for MDI Individuals With Type 1 Diabetes to Adjust Recommendations for High Fat Meals and Exercise Management |
|
|
| Completed | N/A | 15 | Canada | Sensor augmented MDI therapy plus mobile application | McGill University | Type 1 Diabetes | 02/23 | 02/23 | | |
| Recruiting | N/A | 79 | Canada, RoW | Administration of standardized questionnaires, Physical activity tracker, Dietary log | McGill University Health Centre/Research Institute of the McGill University Health Centre | Diabetes Mellitus | 05/23 | 06/23 | | |
NCT04123054: A Novel mHealth Application Guided by an Optimization Algorithm for T1D Sensor-Augmented Insulin Injection Users |
|
|
| Completed | N/A | 84 | Canada | Mobile App, Mobile App + Basal-Bolus Optimization Algorithm | McGill University | Diabetes Mellitus, Diabetes Mellitus, Type 1 | 12/23 | 01/24 | | |
| Recruiting | N/A | 37 | Canada | Continous exercise, Interval exercise, Reduction of basal insulin by 40%, Reduction of basal insulin by 80% | Institut de Recherches Cliniques de Montreal, McGill University Health Centre/Research Institute of the McGill University Health Centre | Type 1 Diabetes Mellitus | 12/23 | 02/24 | | |
NCT03720197: Registry of Patients Living With Type 1 Diabetes |
|
|
| Recruiting | N/A | 6000 | Canada | Online questionnaire - Phase 1, Online questionnaire - Phase 2, Online questionnaire - Phase 3, Food questionnaire, Pedometer, Waist circumference, Blood and urine tests, List of medications, Continuous glucose monitor | Institut de Recherches Cliniques de Montreal | Type 1 Diabetes Mellitus | 03/26 | 03/26 | | |
NCT04243629: Co-administration of Pramlintide and Insulin Via an Automated Dual-hormone Artificial Pancreas System in Adults With Type 1 Diabetes |
|
|
| Recruiting | N/A | 26 | Canada | Rapid-Acting Insulin, Placebo, Pramlintide Acetate, Artificial Pancreas | McGill University, Canadian Institutes of Health Research (CIHR) | Diabetes Mellitus, Type 1, Type 1 Diabetes, Postprandial Hyperglycemia | 04/24 | 04/24 | | |
MiTy Tykes, NCT05025852: The Effect of In-utero Exposure to Metformin in 5-11 Year Old Offspring of Mothers in the MiTy Trial |
|
|
| Recruiting | N/A | 220 | Canada, RoW | | Mount Sinai Hospital, Canada, Sunnybrook Research Institute, Canadian Institutes of Health Research (CIHR) | Diabetes Mellitus, Type 2, Pregnancy in Diabetic, Child Obesity, Child Development | 05/26 | 05/26 | | |
| Gula, Lorne |
PEFA-VT, NCT03870854: Paced Electrogram Feature Analysis (PEFA) for Ablation Targeting in Ischaemic Ventricular Tachycardia |
|
|
| Recruiting | N/A | 40 | Canada | PEFA VT ablation technique, Paced electrogram feature analysis or 'PEFA' | Dr. Damian Redfearn | Ischemic Ventricular Tachycardia (VT) | 08/24 | 09/25 | | |
| Recruiting | N/A | 1500 | Canada, Japan | | Ottawa Heart Institute Research Corporation, Ontario Ministry of Health and Long Term Care, Canadian Institutes of Health Research (CIHR) | Cardiac Sarcoidosis | 12/25 | 12/25 | | |
| Qureshi, Salman A |
| Completed | N/A | 3622 | Europe, Canada, US, RoW | 7 days of adequate antibiotic treatment, 14 days of adequate antibiotic treatment. | Sunnybrook Health Sciences Centre | Bacteremia, Intensive Care, Critically Ill, Sepsis, Mortality, Antimicrobial | 05/23 | 08/23 | | |
| Varennes, Benoit de |
AKITA, NCT05126303: Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery |
|
|
| Terminated | 2 | 177 | Europe, Canada, US, RoW | RMC-035, ROSgard, Placebo | Guard Therapeutics AB | Acute Kidney Injury | 04/23 | 07/23 | | |
| Suri, Rita |
| Recruiting | 3 | 2750 | Europe, Canada, RoW | Spironolactone 25Mg Tablet, Placebo Oral Tablet | Population Health Research Institute, Canadian Institutes of Health Research (CIHR) | Endstage Renal Disease | 12/24 | 01/25 | | |
PHOSPHATE, NCT03573089: Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease |
|
|
| Recruiting | N/A | 3600 | Europe, Canada, RoW | Liberal phosphate target, Intensive phosphate target | The University of Queensland, National Health and Medical Research Council, Australia, Applied Health Research Centre, Cambridge University Hospitals NHS Foundation Trust, University of Otago | Kidney Failure, Chronic, Hyperphosphatemia | 12/27 | 12/28 | | |
| Verma, Atul |
OCEAN, NCT02168829: Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial |
|
|
| Active, not recruiting | 4 | 1284 | Europe, Canada, RoW | Rivaroxaban, Xarelto, Acetylsalicylic acid, Aspirin, ASA | Ottawa Heart Institute Research Corporation, Canadian Institutes of Health Research (CIHR), Bayer, Biotronik Canada Inc | Atrial Fibrillation, Stroke | 07/25 | 08/25 | | |
| Not yet recruiting | N/A | 30 | Canada | AcQMap Imaging and Mapping, AcQMap | Acutus Medical | Recurrent Atrial Fibrillation | 03/19 | 05/20 | | |
| Recruiting | N/A | 502 | Canada | Catheter ablation, Atrial Fibrillation Ablation | Ottawa Heart Institute Research Corporation, Heart and Stroke Foundation of Canada | Atrial Fibrillation | 12/24 | 12/24 | | |
NCT04893317: Cryoablation for Monomorphic Ventricular Tachycardia (CryoCure-VT) |
|
|
| Active, not recruiting | N/A | 64 | Europe, Canada, RoW | Ablation in the ventricles with the Adagio Medical VT Cryoablation System | Adagio Medical | Monomorphic Ventricular Tachycardia | 06/24 | 09/24 | | |
| Active, not recruiting | N/A | 200 | Europe, Canada, US | Adagio AF Cryoablation System (iCLAS™) | Adagio Medical | Persistent Atrial Fibrillation | 08/23 | 08/24 | | |
| Recruiting | N/A | 78 | Europe, Canada, RoW | Atrial ablation for subject scheduled for a de novo endocardial ablation of symptomatic, drug-refractory PsAF. | Adagio Medical | Atrial Fibrillation | 10/24 | 05/25 | | |
| Recruiting | N/A | 435 | Europe, Canada, US, RoW | Pulsed Field Ablation | Abbott Medical Devices | Atrial Arrhythmia, Atrial Fibrillation, Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation | 01/26 | 01/26 | | |
NCT05015660: Conduction System Pacing With Left Bundle Branch Pacing as Compared to Standard Right Ventricular Pacing |
|
|
| Recruiting | N/A | 1300 | Canada | Left bundle branch pacing lead (Select Secure 3830 lead), Right ventricular active fixation lead | McGill University Health Centre/Research Institute of the McGill University Health Centre, Heart and Stroke Foundation of Canada, Canadian Institutes of Health Research (CIHR) | Pacemaker DDD, Heart Block | 07/26 | 07/27 | | |
| Recruiting | N/A | 615 | Europe, Canada, Japan, US, RoW | Wide Circumferential Pulmonary Vein Antrum Isolation (PVAI), Pulmonary Vein Antrum Isolation Plus Driver Ablation (PVAI+drivers), Pulmonary Vein Antrum Isolation Plus Box Isolation of Posterior Wall (PVAI+box) | McGill University Health Centre/Research Institute of the McGill University Health Centre, Montreal Heart Institute | Atrial Fibrillation | 08/26 | 01/27 | | |
NCT05337241: Saline Enhanced Radiofrequency (SERF) Needle Ablation for Refractory VT |
|
|
| Not yet recruiting | N/A | 130 | Canada, US | Saline Enhanced Radiofrequency (SERF) Ablation, Intramural Needle Ablation | Thermedical, Inc. | Refractory Ventricular Tachycardia | 11/24 | 12/24 | | |
NCT03643224: DiamondTemp™ System for the Treatment of Persistent Atrial Fibrillation |
|
|
| Active, not recruiting | N/A | 376 | Europe, Canada, US, RoW | Radiofrequency Ablation | Medtronic Cardiac Rhythm and Heart Failure | Persistent Atrial Fibrillation, Atrial Fibrillation | 10/24 | 12/24 | | |
ADVANTAGE AF, NCT05443594: A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation |
|
|
| Active, not recruiting | N/A | 669 | Europe, Canada, US | Phase 1: FARAPULSE Ablation System, Phase 2: FARAPULSE Ablation System | Boston Scientific Corporation | Persistent Atrial Fibrillation | 03/25 | 03/25 | | |
| Roberge, David |
NCT03550391: Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases |
|
|
| Recruiting | 3 | 206 | Canada, US | Memantine, Hippocampal-avoidant (HA-WBRT) Radiotherapy, Stereotactic Radiosurgery (SRS) | Canadian Cancer Trials Group, Alliance for Clinical Trials in Oncology, NRG Oncology | Brain Metastases | 06/27 | 12/27 | | |
METIS, NCT02831959: Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC). |
|
|
| Active, not recruiting | 3 | 270 | Europe, Canada, US, RoW | NovoTTF-200M device, Best Standard of Care | NovoCure GmbH | Brain Metastases From Non-small Cell Lung Cancer (NSCLC) | 12/24 | 12/24 | | |
NCT04114981: Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating Patients With Resected Metastatic Brain Disease |
|
|
| Active, not recruiting | 3 | 242 | Canada, US | Single Fraction Stereotactic Radiosurgery, Stereotactic Radiosurgery, Fractionated Stereotactic Radiosurgery, Quality-of-Life Assessment, Questionnaire Administration | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Metastatic Malignant Neoplasm in the Brain | 03/25 | 03/28 | | |
NCT04467515: A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer |
|
|
| Terminated | 1/2 | 13 | Canada, US | CAM-H2 | Precirix | Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment | 12/23 | 12/23 | | |
NCT05317026: Increased Early Pain Relief by Adding Vertebroplasty to SBRT |
|
|
| Recruiting | N/A | 50 | Canada | Vertebroplasty, Stereotactic Body Radiation Therapy only, SBRT | Centre hospitalier de l'Université de Montréal (CHUM) | Spine Metastases, Radiation Therapy, Pain | 04/24 | 08/26 | | |
NCT04002479: Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer |
|
|
| Recruiting | N/A | 37 | Canada | Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT) | Alpha Tau Medical LTD. | Pancreatic Cancer, Unresectable Pancreatic Cancer, Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma | 10/24 | 10/26 | | |
| Recruiting | N/A | 1000 | Europe, Canada, US, RoW | Neurosurgery, Radiation therapy, Embolization | Centre hospitalier de l'Université de Montréal (CHUM), Centre Hospitalier Régional et Universitaire de Brest | Unruptured Brain Arteriovenous Malformation, Ruptured Brain Arteriovenous Malformation, Arteriovenous Malformations, AVM, BAVM | 01/35 | 01/36 | | |
| Investigator, Principal |
| Recruiting | 4 | 140 | Europe | Opicapone 50 mg, BIA 9-1067, Matching placebo | Bial - Portela C S.A., Bial - Portela & Ca, S.A. | Parkinson Disease | 12/22 | 12/22 | | |
NCT04248205: Ketamine for Post-operative Analgesia in Hemorrhoidectomy |
|
|
| Recruiting | 4 | 100 | US | Ketamine | University of Oklahoma | Hemorrhoids | 01/25 | 07/25 | | |
NCT05400369: A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease |
|
|
| Recruiting | 4 | 268 | RoW | Sitafloxacin, Gracevit, Moxifloxacin Hydrochloride, Avelox | Daiichi Sankyo | COPD Exacerbation Acute | 09/24 | 12/24 | | |
TrEAT_TD2, NCT05677282: Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, With Loperamide Adjunct |
|
|
| Recruiting | 4 | 150 | RoW | Rifaximin 550 MG, Azithromycin 500 MG, Loperamide | Henry M. Jackson Foundation for the Advancement of Military Medicine, Infectious Diseases Clinical Research Program, Uniformed Services University of the Health Sciences | Diarrhoea;Acute, Diarrhea Travelers | 09/24 | 12/24 | | |
POUR, NCT04994431: Post-Operative Urinary Retention () in Thoracic Surgery Patients Receiving Prophylactic Tamsulosin |
|
|
| Recruiting | 4 | 60 | US | Tamsulosin Hydrochloride | Feiran Lou, UMass Memorial Health Care | Thoracic Diseases, Urinary Retention | 06/25 | 12/25 | | |
NCT02932410 / 2016-001062-28: A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH) |
|
|
| Recruiting | 3 | 300 | Europe, Canada, US, RoW | Macitentan, ACT-064992, Standard-of-care | Actelion | Pulmonary Arterial Hypertension | 11/23 | 12/24 | | |
| Active, not recruiting | 3 | 590 | Europe, Canada, Japan, US, RoW | DS-1062a, Datopotamab deruxtecan (Dato-DXd), Docetaxel | Daiichi Sankyo, AstraZeneca | Non-small Cell Lung Cancer | 05/24 | 06/24 | | |
|
|
| Recruiting | 3 | 490 | Europe, Japan, RoW | Trastuzumab deruxtecan, T-DXd, DS-8201a, ENHERTU®, Ramucirumab, CYRAMZA®, Paclitaxel | Daiichi Sankyo, AstraZeneca | Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 10/25 | 02/26 | | |
|
|
|
|
TNX-N, NCT03503136: Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC |
|
|
| Not yet recruiting | 3 | 632 | RoW | docetaxel, nedaplatin, and capecitabine, TNX induction chemotherapy, nedaplatin, N, docetaxel, cisplatin, and fluorouracil, TPF induction chemotherapy, cisplatin, P, docetaxel, cisplatin, and capecitabine, TPX induction chemotherapy, docetaxel, nedaplatin, and fluorouracil, TNF induction chemotherapy | Sun Yat-sen University, Tongji Hospital, Wuhan Union Hospital, China, Peking University, Air Force Military Medical University, China, Second Affiliated Hospital of Soochow University, The First Affiliated Hospital of Guangdong Pharmaceutical University, First People's Hospital of Foshan, Fifth Affiliated Hospital, Sun Yat-Sen University, Cancer Hospital of Guizhou Province, Xiangya Hospital of Central South University, Jilin Provincial Tumor Hospital, Henan Cancer Hospital, Hunan Cancer Hospital, Cancer Hospital of Guangxi Medical University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Zhejiang Cancer Hospital | Nasopharyngeal Carcinoma | 06/24 | 06/26 | | |
NCT05839899: Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location |
|
|
| Recruiting | 3 | 50 | US | Mifepristone plus one dose Misoprostol, Mifepristone plus two doses Misoprostol | Planned Parenthood League of Massachusetts | Abortion | 07/24 | 09/24 | | |
| Active, not recruiting | 3 | 586 | Europe, Canada, Japan, US, RoW | Patritumab Deruxtecan, HER3-DXd, U3-1402, Platinum-based chemotherapy | Daiichi Sankyo, DAIICHI SANKYO. INC., Daiichi Sankyo, Inc. | Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion | 08/24 | 06/26 | | |
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy |
|
|
| Recruiting | 3 | 102 | Europe, Canada, US, RoW | Ampreloxetine, TD-9855, Placebo | Theravance Biopharma | Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy | 12/24 | 01/27 | | |
| Active, not recruiting | 3 | 899 | Europe, Canada, Japan, US, RoW | Tafasitamab, Monjuvi, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo | MorphoSys AG | Diffuse Large B-cell Lymphoma | 06/25 | 05/26 | | |
|
|
|
| Active, not recruiting | 3 | 1 | US | StrataGraft | Stratatech, a Mallinckrodt Company, Biomedical Advanced Research and Development Authority | Skin Wound, Burns, Trauma-related Wound | 05/24 | 05/24 | | |
NCT05847348: 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients |
|
|
| Recruiting | 3 | 110 | RoW | 68Ga-PSMA-11, Illucix, gallium Ga 68 Gozetotide, PET/CT or PET/MRI, Imaging by PET | Telix Pharmaceuticals (Innovations) Pty Limited, Grand Pharmaceutical (China) Co., Ltd. | Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer, BCR Prostate Carcinoma | 12/25 | 07/26 | | |
| Active, not recruiting | 3 | 1600 | Europe, Canada, Japan, US, RoW | DS-8201a, Trastuzumab deruxtecan (T-DXd), T-DM1, Trastuzumab emtansine (T-DM1) | Daiichi Sankyo, Inc., AstraZeneca, NSABP Foundation Inc, German Breast Group, Spanish Breast Cancer Research Group (SOLTI) | HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer | 12/25 | 12/30 | | |
|
|
FREEDOM, NCT05817812: A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa |
|
|
| Active, not recruiting | 3 | 93 | Europe, RoW | Efanesoctocog alfa, BIVV001 | Swedish Orphan Biovitrum, Syneos Health | Hemophilia A, Severe | 05/26 | 05/26 | | |
| Recruiting | 3 | 740 | Europe, Canada, Japan, US, RoW | Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA® | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Metastatic Non Small Cell Lung Cancer | 02/28 | 04/28 | | |
|
|
TROPION-Lung07, NCT05555732: Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 975 | Europe, Canada, Japan, US, RoW | Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, Keytruda, Pemetrexed, Alimta, Pemfexy, Carboplatin, Cisplatin | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Metastatic Non Small Cell Lung Cancer | 08/27 | 08/27 | | |
ARTEMIS, NCT04797884: Electromagnetic Fields Versus Placebo For Child-Pugh A and B Patients With Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 2/3 | 166 | US | TheraBionic Device, Placebo Device, Quality of Life Assessment | THERABIONIC INC., National Cancer Institute (NCI) | Hepatocellular Carcinoma | 10/24 | 10/24 | | |
TRIPHASE, NCT06101745: Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic Surgery |
|
|
| Recruiting | 2/3 | 336 | Europe | Nizaracianine Triflutate, ZW800-1, Placebo Comparator, Sugar | Curadel Surgical Innovations, Inc., Leiden University Medical Center, Erasmus Medical Center | Injury of Ureter During Surgery (Disorder) | 10/25 | 11/25 | | |
| Active, not recruiting | 2 | 46 | Europe, Canada, US, RoW | Belcesiran, Placebo | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Alpha 1-Antitrypsin Deficiency | 12/23 | 12/26 | | |
AAVIATE, NCT04514653: RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) |
|
|
| Recruiting | 2 | 115 | US | RGX-314 Dose 1, Combination Product, RGX-314 Dose 2, Ranibizumab, RGX-314 Dose 3, Local steroid, Topical steroid | AbbVie, AbbVie | Neovascular Age-Related Macular Degeneration (nAMD) | 10/23 | 01/24 | | |
NCT04832724: RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD) |
|
|
| Completed | 2 | 60 | US | RGX-314 | AbbVie | Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, Wet Age-related Macular Degeneration | 10/23 | 03/24 | | |
Orchid 1, NCT06132919: Efficacy and Safety of MC2-25 Cream & Vehicle in Women With Vulvar Lichen Sclerosus (VLS) |
|
|
| Recruiting | 2 | 40 | Europe | MC2-25 cream, MC2-25 vehicle | MC2 Therapeutics | Vulvar Lichen Sclerosus | 11/24 | 11/24 | | |
| Active, not recruiting | 2 | 13 | US | AG Tx, Meshed Autograft, SOMA Tx, StrataGraft skin tissue Overlay of Meshed Autograft (SOMA) | Stratatech, a Mallinckrodt Company | Full Thickness Thermal Burn | 12/24 | 12/24 | | |
| Recruiting | 2 | 400 | Japan, US, RoW | HER3-DXd, Patritumab Deruxtecan, U3-1402 | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer | 06/25 | 04/26 | | |
NCT05198310: Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor |
|
|
| Completed | 2 | 145 | Europe, US, RoW | KPL-404, Placebo | Kiniksa Pharmaceuticals, Ltd. | Arthritis, Rheumatoid | 02/24 | 05/24 | | |
EAD501, NCT05607615: A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease |
|
|
| Recruiting | 2 | 90 | US | Hydroxypropyl Beta Cyclodextrin, Trappsol Cyclo, Placebo, 0.5N saline | Cyclo Therapeutics, Inc. | Alzheimer's Disease | 03/24 | 03/24 | | |
| Completed | 2 | 64 | Europe, US | DS-1211b, Placebo | Daiichi Sankyo, PXE International | Pseudoxanthoma Elasticum | 11/23 | 11/23 | | |
MAST, NCT06355583: Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant () Trial |
|
|
| Not yet recruiting | 2 | 50 | Europe | EBX-102, IMT capsules, Placebo | Imperial College London | Acute Lymphoblastic Leukaemia, Acute Leukemia of Ambiguous Lineage, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia | 02/26 | 05/27 | | |
NCT04870905: Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma |
|
|
| Not yet recruiting | 2 | 100 | RoW | Tis-U-Sol | Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Union hospital of Fujian Medical University, Zhujiang Hospital, Guangdong Provincial People's Hospital | Nasopharyngeal Neoplasms | 05/24 | 05/26 | | |
| Active, not recruiting | 2 | 187 | Europe, Japan, US, RoW | Ifinatamab Deruxtecan (I-DXd), DS-7300a | Daiichi Sankyo, Merck Sharp & Dohme LLC | Extensive-stage Small-cell Lung Cancer | 01/25 | 04/25 | | |
NCT05029336: Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases |
|
|
| Recruiting | 2 | 20 | US | Depletion of CD3/CD19 in an autologous stem cell transplant, CD3/CD19 depletion using cliniMACs device | Stephan Grupp MD PhD | Systemic Lupus Erythematosus, Systemic Sclerosis | 12/26 | 05/31 | | |
NCT04935762: A Study of CST-103 Co-administered With CST-107 in Subjects With Parkinson's Disease Having Freezing of Gait (CLIN-012) |
|
|
| Not yet recruiting | 2 | 25 | RoW | CST-103, CST-107, matching placebo | CuraSen Therapeutics, Inc. | Freezing of Gait Symptoms in Parkinson's Disease | 12/24 | 03/25 | | |
NCT04977024: SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer |
|
|
| Recruiting | 2 | 240 | US | COVID-19 Vaccine, Diagnostic Laboratory Biomarker Analysis, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1, COH04S1, SARS-CoV-2 Vaccine COH04S1, sMVA-based SARS-CoV-2 Vaccine COH04S1, GEO-CM04S1 | GeoVax, Inc., National Cancer Institute (NCI) | COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma | 03/25 | 03/26 | | |
NCT06038578: A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer |
|
|
| Recruiting | 2 | 146 | Japan, US, RoW | TRK-950, Ramucirumab, CYRAMZA®, Paclitaxel | Toray Industries, Inc | Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 08/25 | 08/25 | | |
NCT05205330: A Phase Ib/IIa Study of CR6086 in Combination With Balstilimab in pMMR-MSS Metastatic Colorectal Cancer Patients |
|
|
| Active, not recruiting | 1/2 | 28 | Europe | CR6086, AGEN2034, Balstilimab | Rottapharm Biotech, Agenus Inc. | Refractory Metastatic Colorectal Cancer, Solid Tumor, Metastatic Microsatellite-stable Colorectal Cancer, Mismatch Repair Protein Proficient | 10/23 | 12/24 | | |
NCT05638802: A Study of DS-7011a in Patients With Systemic Lupus Erythematosus |
|
|
| Recruiting | 1/2 | 24 | US | DS-7011a, Placebo | Daiichi Sankyo | Systemic Lupus Erythematosus | 03/25 | 03/25 | | |
| Active, not recruiting | 1/2 | 300 | Europe, US | ASTX029 | Astex Pharmaceuticals, Inc. | Solid Tumor, Adult | 06/24 | 12/25 | | |
NCT05979831: A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome |
|
|
| Recruiting | 1/2 | 12 | Europe | DS-2325a, Placebo | Daiichi Sankyo | Netherton Syndrome | 11/24 | 11/24 | | |
| Recruiting | 1/2 | 145 | US, RoW | SQ3370 | Shasqi, Inc. | Cancer | 08/24 | 07/26 | | |
| Recruiting | 1/2 | 250 | Japan, US | Ifinatamab deruxtecan (I-DXd) | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Malignant Solid Tumor | 12/24 | 03/27 | | |
| Active, not recruiting | 1/2 | 666 | Europe, Canada, US, RoW | Epcoritamab, GEN3013, DuoBody®-CD3xCD20, EPKINLY™ | Genmab, AbbVie | DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL, MCL, Small Lymphocytic Lymphoma (SLL), Marginal Zone Lymphoma (MZL) | 03/25 | 01/29 | | |
|
|
|
|
NCT05693025: Evaluation of the Walk With Ease Program for Fall Prevention |
|
|
| Recruiting | 1/2 | 240 | US | Group Exercise, Behavioral Training | Iowa State University | Exercise, Frailty, Arthritis, Accidental Falls | 05/25 | 05/26 | | |
| Recruiting | 1/2 | 430 | Japan, US | DS-3939a | Daiichi Sankyo | Advanced Solid Tumor, Metastatic Solid Tumor | 03/26 | 07/27 | | |
NCT03793478 / 2016-002919-18: Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood |
|
|
| Recruiting | 1/2 | 65 | Europe, Canada, US, RoW | Quizartinib, Quizartinib dihydrochloride, Vanflyta, Fludarabine, Cytarabine, Intrathecal (IT) triple chemotherapy prophylaxis, Etoposide | Daiichi Sankyo, Inc., Innovative Therapies For Children with Cancer Consortium, Children's Oncology Group | Acute Myeloid Leukemia | 05/27 | 05/27 | | |
| Recruiting | 1 | 309 | Europe, Japan, US, RoW | HER3-DXd (FL-DP), HER3-DXd (CTM-1 Lyo-DP), HER3-DXd (CTM-3 Lyo-DP) | Daiichi Sankyo | Non-Small Cell Lung Cancer (NSCLC) | 03/26 | 12/26 | | |
|
|
NCT05203692: A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects |
|
|
| Completed | 1 | 80 | US | DS-7011a, Placebo | Daiichi Sankyo, Inc. | Systemic Lupus Erythematosus | 01/23 | 03/23 | | |
NCT05388903: A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects |
|
|
| Completed | 1 | 64 | US | DS-2325a, Placebo | Daiichi Sankyo, Inc. | Netherton Syndrome | 01/23 | 01/23 | | |
NCT05484414: Safety and Pharmacokinetics of SAD/MAD Oral Doses of SRP-3D (DA) |
|
|
| Active, not recruiting | 1 | 56 | US | SRP-3D (diethylamide), SRP-3D (DA), Placebo, Control | South Rampart Pharma, LLC | Pain | 10/23 | 02/24 | | |
NCT05844202: Safety, Tolerability and Immunogenicity of Alveavax-v1.2, a BA.2/Omicron-optimized, DNA Vaccine for COVID-19 Prevention |
|
|
| Completed | 1 | 130 | RoW | Alveavax-v1.2, Alveavax, Janssen Ad26.COV2.S, Janssen | Alvea Holdings, LLC | Sars-CoV-2 Infection | 03/23 | 03/23 | | |
NCT05583669: A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects |
|
|
| Completed | 1 | 24 | US | DS-2325a, Placebo | Daiichi Sankyo, Inc. | Netherton Syndrome | 05/23 | 05/23 | | |
